SEC62 and breast carcinoma: Overall survival was also shown to be significantly worse in a cohort of 53 patients with breast cancer, whose SEC62 overexpression was assessed by Takacs et al. by also evaluating their Sec62 staining intensity by IHC analyses of tissue samples (Takacs et al., 2019).